Velacur for Fatty Liver Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the drug Velacur for treating fatty liver disease?
How does the drug Velacur differ from other treatments for fatty liver disease?
What is the purpose of this trial?
This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.
Research Team
Miriam Vos, MD
Principal Investigator
Emory University
Eligibility Criteria
This trial is for children and adolescents aged 2-20 years who may have a condition called MASLD, which involves fat buildup in the liver. The study will include those likely to have this condition and excludes anyone for whom the tests are not safe or suitable.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Testing
Participants undergo Velacur ultrasound and/or blood biomarker collection to assess hepatic steatosis and fibrosis
Follow-up
Participants are monitored for safety and effectiveness of the diagnostic tests
Treatment Details
Interventions
- Velacur
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
Sonic Incytes
Industry Sponsor